432 related articles for article (PubMed ID: 33838625)
1. Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.
Friedman GK; Johnston JM; Bag AK; Bernstock JD; Li R; Aban I; Kachurak K; Nan L; Kang KD; Totsch S; Schlappi C; Martin AM; Pastakia D; McNall-Knapp R; Farouk Sait S; Khakoo Y; Karajannis MA; Woodling K; Palmer JD; Osorio DS; Leonard J; Abdelbaki MS; Madan-Swain A; Atkinson TP; Whitley RJ; Fiveash JB; Markert JM; Gillespie GY
N Engl J Med; 2021 Apr; 384(17):1613-1622. PubMed ID: 33838625
[TBL] [Abstract][Full Text] [Related]
2. Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
Bernstock JD; Bag AK; Fiveash J; Kachurak K; Elsayed G; Chagoya G; Gessler F; Valdes PA; Madan-Swain A; Whitley R; Markert JM; Gillespie GY; Johnston JM; Friedman GK
Hum Gene Ther; 2020 Oct; 31(19-20):1132-1139. PubMed ID: 32657154
[TBL] [Abstract][Full Text] [Related]
3. Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.
Waters AM; Johnston JM; Reddy AT; Fiveash J; Madan-Swain A; Kachurak K; Bag AK; Gillespie GY; Markert JM; Friedman GK
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):7-16. PubMed ID: 28319448
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.
Markert JM; Razdan SN; Kuo HC; Cantor A; Knoll A; Karrasch M; Nabors LB; Markiewicz M; Agee BS; Coleman JM; Lakeman AD; Palmer CA; Parker JN; Whitley RJ; Weichselbaum RR; Fiveash JB; Gillespie GY
Mol Ther; 2014 May; 22(5):1048-55. PubMed ID: 24572293
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus -1 G207 in Pediatric Malignant Supratentorial Brain Tumors.
Bernstock JD; Wright Z; Bag AK; Gessler F; Gillespie GY; Markert JM; Friedman GK; Johnston JM
World Neurosurg; 2019 Feb; 122():e1592-e1598. PubMed ID: 30481622
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Todo T; Rabkin SD; Martuza RL
Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
[TBL] [Abstract][Full Text] [Related]
7. The safety and accuracy of intratumoral catheter placement to infuse viral immunotherapies in children with malignant brain tumors: a multi-institutional study.
Barkley A; Butler E; Park C; Friedman A; Landi D; Ashley DM; Bigner D; Bernstock JD; Friedman GK; Johnston JM; Thompson EM
J Neurosurg Pediatr; 2024 Apr; 33(4):359-366. PubMed ID: 38215438
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.
Gállego Pérez-Larraya J; Garcia-Moure M; Labiano S; Patiño-García A; Dobbs J; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; Puigdelloses M; Laspidea V; Astigarraga I; Lopez-Ibor B; Cruz O; Oscoz Lizarbe M; Hervas-Stubbs S; Alkorta-Aranburu G; Tamayo I; Tavira B; Hernandez-Alcoceba R; Jones C; Dharmadhikari G; Ruiz-Moreno C; Stunnenberg H; Hulleman E; van der Lugt J; Idoate MÁ; Diez-Valle R; Esparragosa Vázquez I; Villalba M; de Andrea C; Núñez-Córdoba JM; Ewald B; Robbins J; Fueyo J; Gomez-Manzano C; Lang FF; Tejada S; Alonso MM
N Engl J Med; 2022 Jun; 386(26):2471-2481. PubMed ID: 35767439
[TBL] [Abstract][Full Text] [Related]
10. Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
Baugh R; Khalique H; Page E; Lei-Rossmann J; Wan PK; Johanssen T; Ebner D; Ansorge O; Seymour LW
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724464
[TBL] [Abstract][Full Text] [Related]
11. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence.
Kanai R; Tomita H; Shinoda A; Takahashi M; Goldman S; Okano H; Kawase T; Yazaki T
Gene Ther; 2006 Jan; 13(2):106-16. PubMed ID: 16163378
[TBL] [Abstract][Full Text] [Related]
12. Intraventricular immunovirotherapy; a translational step forward.
Bernstock JD; Blitz S; Kang KD; Friedman GK
Oncotarget; 2023 Jan; 14():40-43. PubMed ID: 36634220
[TBL] [Abstract][Full Text] [Related]
13. Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas.
Omar NB; Bentley RT; Crossman DK; Foote JB; Koehler JW; Markert JM; Platt SR; Rissi DR; Shores A; Sorjonen D; Yanke AB; Gillespie GY; Chambers MR
Neurosurg Focus; 2021 Feb; 50(2):E5. PubMed ID: 33524948
[TBL] [Abstract][Full Text] [Related]
14. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.
Todo T; Feigenbaum F; Rabkin SD; Lakeman F; Newsome JT; Johnson PA; Mitchell E; Belliveau D; Ostrove JM; Martuza RL
Mol Ther; 2000 Dec; 2(6):588-95. PubMed ID: 11124059
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.
Forsyth P; Roldán G; George D; Wallace C; Palmer CA; Morris D; Cairncross G; Matthews MV; Markert J; Gillespie Y; Coffey M; Thompson B; Hamilton M
Mol Ther; 2008 Mar; 16(3):627-32. PubMed ID: 18253152
[TBL] [Abstract][Full Text] [Related]
16. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.
Markert JM; Liechty PG; Wang W; Gaston S; Braz E; Karrasch M; Nabors LB; Markiewicz M; Lakeman AD; Palmer CA; Parker JN; Whitley RJ; Gillespie GY
Mol Ther; 2009 Jan; 17(1):199-207. PubMed ID: 18957964
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma.
Kieran MW; Goumnerova L; Manley P; Chi SN; Marcus KJ; Manzanera AG; Polanco MLS; Guzik BW; Aguilar-Cordova E; Diaz-Montero CM; DiPatri AJ; Tomita T; Lulla R; Greenspan L; Aguilar LK; Goldman S
Neuro Oncol; 2019 Mar; 21(4):537-546. PubMed ID: 30883662
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice.
Bernstock JD; Vicario N; Li R; Nan L; Totsch SK; Schlappi C; Gessler F; Han X; Parenti R; Beierle EA; Whitley RJ; Aban I; Gillespie GY; Markert JM; Friedman GK
Cancer Gene Ther; 2020 Apr; 27(3-4):246-255. PubMed ID: 30918335
[TBL] [Abstract][Full Text] [Related]
19. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.
Markert JM; Medlock MD; Rabkin SD; Gillespie GY; Todo T; Hunter WD; Palmer CA; Feigenbaum F; Tornatore C; Tufaro F; Martuza RL
Gene Ther; 2000 May; 7(10):867-74. PubMed ID: 10845725
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers.
Kang KD; Bernstock JD; Totsch SK; Gary SE; Rocco A; Nan L; Li R; Etminan T; Han X; Beierle EA; Eisemann T; Wechsler-Reya RJ; Bae S; Whitley R; Gillespie GY; Markert JM; Friedman GK
Clin Cancer Res; 2022 Dec; 28(24):5419-5430. PubMed ID: 36239623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
